Edition:
India

Genomic Health Inc (GHDX.OQ)

GHDX.OQ on NASDAQ Stock Exchange Global Select Market

51.38USD
1:30am IST
Change (% chg)

$-0.50 (-0.96%)
Prev Close
$51.88
Open
$52.58
Day's High
$53.20
Day's Low
$51.26
Volume
91,414
Avg. Vol
83,414
52-wk High
$53.52
52-wk Low
$26.54

Chart for

About

Genomic Health, Inc. is a healthcare company that provides genomic-based diagnostic tests to personalize cancer treatment. The Company develops and commercializes genomic-based clinical laboratory services. The Company's Oncotype IQ Genomic Intelligence Platform is consisted of its flagship line of Oncotype DX gene expression... (more)

Overall

Beta: 0.72
Market Cap(Mil.): $1,144.69
Shares Outstanding(Mil.): 34.65
Dividend: --
Yield (%): --

Financials

BRIEF-Genomic Health Q1 Loss Per Share $0.11

* GENOMIC HEALTH ANNOUNCES FIRST QUARTER 2018 FINANCIAL RESULTS AND REPORTS RECENT BUSINESS PROGRESS

03 May 2018

BRIEF-Tailorx Results Aid In Assessing The Effect Of Chemotherapy In Women With Early-Stage Breast Cancer And Oncotype Dx Breast Recurrence Score Results Of 11 To 25

* LANDMARK TAILORX RESULTS AID IN ASSESSING THE EFFECT OF CHEMOTHERAPY IN WOMEN WITH EARLY-STAGE BREAST CANCER AND ONCOTYPE DX BREAST RECURRENCE SCORE® RESULTS OF 11 TO 25

15 Mar 2018

BRIEF-Genomic Health Reports Q4 Earnings Per Share $0.05

* GENOMIC HEALTH ANNOUNCES 2017 FOURTH QUARTER AND YEAR-END FINANCIAL RESULTS, PROVIDES 2018 FINANCIAL OUTLOOK

09 Mar 2018

BRIEF-Genomic Health Reports Q4 Earnings Per Share $0.05

* GENOMIC HEALTH ANNOUNCES 2017 FOURTH QUARTER AND YEAR-END FINANCIAL RESULTS, PROVIDES 2018 FINANCIAL OUTLOOK

08 Mar 2018

BRIEF-Genomic Health Expands Offering To Prostate Cancer Patients With Launch Of Oncotype DX AR-V7 Nucleus Detect Test To Predict Treatment Response In Metastatic Disease

* GENOMIC HEALTH EXPANDS OFFERING TO PROSTATE CANCER PATIENTS WITH LAUNCH OF ONCOTYPE DX® AR-V7 NUCLEUS DETECT™ TEST TO PREDICT TREATMENT RESPONSE IN METASTATIC DISEASE Source text for Eikon: Further company coverage:

26 Feb 2018

BRIEF-Genomic Health - Oncotype DX Genomic Prostate Score™ Test Increases Use Of Active Surveillance

* ONCOTYPE DX® GENOMIC PROSTATE SCORE™ TEST INCREASES USE OF ACTIVE SURVEILLANCE BY 30 PERCENT IN LOW-RISK PATIENTS, RESULTING IN GREATER ADHERENCE TO GUIDELINE-BASED CARE Source text for Eikon: Further company coverage:

05 Feb 2018

Earnings vs. Estimates